A newly launched clinical trial is set to examine whether oral vancomycin, a well-known glycopeptide antibiotic, could offer a new treatment option for people living with both ulcerative colitis (UC) and primary sclerosing cholangitis (PSC), a rare liver condition that frequently accompanies inflammatory bowel disease. The study, registered on ClinicalTrials.gov, represents an encouraging step toward better understanding how targeted antibiotic therapy might help this specific and often under-studied patient population.
The trial will enroll adult participants who have active UC alongside PSC, randomly assigning them to receive either oral vancomycin (250 mg twice daily) or a matching placebo for four weeks. Those who complete the initial phase will have the option to continue with an additional four weeks of open-label vancomycin, allowing researchers to gather more insight into longer-term tolerability. Throughout the study, participants will undergo regular clinic visits that include Mayo score assessments, endoscopy, and blood and stool testing to monitor both UC activity and liver health.
What makes this study particularly promising is its thoughtful, feasibility-focused design. Rather than jumping straight to large-scale efficacy claims, the researchers are first asking foundational questions: Can enough participants be recruited and retained? Will adherence to the treatment protocol be strong? These are essential building blocks for any future, larger trial, and a well-run pilot study like this one helps ensure that subsequent research is built on a solid foundation.
Beyond feasibility, the trial will also collect valuable secondary data on safety, early signs of improvement in UC symptoms, liver function markers, and shifts in gut bacterial balance. Since PSC and UC often occur together and can be challenging to manage simultaneously, any research that explores treatments addressing both conditions is a welcome development. Oral vancomycin is already used in clinical settings for certain gastrointestinal infections, so examining its potential role in this dual-diagnosis population builds on existing, familiar ground rather than starting from scratch.
While results are still to come, the initiation of this trial reflects the kind of methodical, patient-centered research that can eventually lead to improved treatment pathways for people managing these intertwined conditions. True North Labs will continue to follow this study as it progresses and share updates on what researchers learn.
This article is for informational purposes only and is not intended as medical advice. Please consult a qualified healthcare provider for guidance on any treatment or clinical trial participation.
Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.
Leave a Reply